TSX gains on big banks strength
Director Kevin Buehler of Precision Biosciences INC (NASDAQ:DTIL) recently purchased 5,076 shares of common stock, according to a Form 4 filing. The transactions, which occurred on June 25, 2025, involved a total value of $21,116. The purchase comes as the stock has declined about 14% over the past week, though InvestingPro analysis suggests the shares are currently undervalued.
The price per share for the purchase ranged from $4.16 to $4.18. Following the transaction, Buehler directly owns 28,137 shares of Precision Biosciences. With a market capitalization of $46 million and analyst price targets ranging from $13 to $60, the company maintains a strong financial health score according to InvestingPro, which offers 8 additional key insights about DTIL’s financial position.
In other recent news, Precision BioSciences announced significant regulatory advancements for its gene editing therapies. The U.S. Food and Drug Administration (FDA) granted Rare Pediatric Disease Designation to Precision’s PBGENE-DMD therapy for Duchenne muscular dystrophy. This designation may qualify the company for a Priority Review Voucher upon potential FDA approval, which could expedite the review of another product. Additionally, Precision’s PBGENE-HBV therapy for chronic hepatitis B received Fast Track designation from the FDA, intended to accelerate its development and review process. The Fast Track designation underscores the urgent need for innovative treatments for chronic hepatitis B, affecting millions globally. At the company’s recent annual shareholder meeting, Kevin J. Buehler and Shari Lisa Piré were elected as Class III directors. Shareholders also ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025. However, a proposal to amend the Certificate of Incorporation did not pass, despite receiving substantial support. These developments highlight Precision BioSciences’ ongoing efforts in advancing its gene editing programs and corporate governance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.